Cargando…
Volasertib for AML: clinical use and patient consideration
Acute myeloid leukemia (AML) is a disease diagnosed mostly in patients >65 years of age. Despite its heterogeneous nature, the different types of AMLs are still managed by standard induction chemotherapy for those who can tolerate it in the beginning. For the elderly and infirm patients, however,...
Autores principales: | Hao, Zhonglin, Kota, Vamsi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514349/ https://www.ncbi.nlm.nih.gov/pubmed/26229484 http://dx.doi.org/10.2147/OTT.S60762 |
Ejemplares similares
-
Strategic and Statistical Considerations on the QT Assessment of Volasertib
por: Wallenstein, Gudrun, et al.
Publicado: (2017) -
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo
por: Schnerch, Dominik, et al.
Publicado: (2017) -
Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia
por: Adachi, Yoshiya, et al.
Publicado: (2017) -
Volasertib preclinical activity in high-risk hepatoblastoma
por: Kats, Dina, et al.
Publicado: (2019) -
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
por: Gjertsen, B T, et al.
Publicado: (2015)